Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether giving nab-paclitaxel, durvalumab, and tremelimumab with or without neoantigen vaccine will work better in treating patients with triple negative breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem raka piersi potrójnie ujemnego z przerzutami
- •Brak receptorów estrogenowych i progesteronowych (wynik poniżej progu)
- •Brak białka HER2 potwierdzone badaniem laboratoryjnym
- •Brak białka PD-L1 potwierdzone badaniem laboratoryjnym
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na aktywność (ECOG 0-1)
- •Wystarczająca liczba białych krwinek, płytek krwi i hemoglobiny
- •Prawidłowe parametry wątroby i nerek
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (30)
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, United States
University of California Davis Comprehensive Cancer Center
Sacramento, United States
UCHealth University of Colorado Hospital
Aurora, United States
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, United States
Yale University
New Haven, United States
UM Sylvester Comprehensive Cancer Center at Aventura
Aventura, United States
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, United States
UM Sylvester Comprehensive Cancer Center at Kendall
Miami, United States
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, United States
Moffitt Cancer Center-International Plaza
Tampa, United States
Moffitt Cancer Center - McKinley Campus
Tampa, United States
Moffitt Cancer Center
Tampa, United States
Moffitt Cancer Center at Wesley Chapel
Wesley Chapel, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, United States
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, United States
Siteman Cancer Center at West County Hospital
Creve Coeur, United States
Washington University School of Medicine
St Louis, United States
Siteman Cancer Center-South County
St Louis, United States
Siteman Cancer Center at Christian Hospital
St Louis, United States
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, United States
NYP/Weill Cornell Medical Center
New York, United States
Wake Forest University at Clemmons
Clemmons, United States
Wake Forest University Health Sciences
Winston-Salem, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, United States
University of Texas Medical Branch
Galveston, United States
VCU Massey Comprehensive Cancer Center
Richmond, United States
Trial contact
Site Public Contact
Jennifer R. Diamond
PRINCIPAL_INVESTIGATOR
Site Public Contact
Alejandra T. Perez
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Aixa E. Soyano
PRINCIPAL_INVESTIGATOR
Site Public Contact
Cesar A. Santa-Maria
PRINCIPAL_INVESTIGATOR
Site Public Contact
William E. Gillanders
PRINCIPAL_INVESTIGATOR
Site Public Contact
Massimo Cristofanilli
PRINCIPAL_INVESTIGATOR
Site Public Contact
Emily H. Douglas
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Kai C. Johnson
PRINCIPAL_INVESTIGATOR
Site Public Contact
Julia Foldi
PRINCIPAL_INVESTIGATOR
Site Public Contact
Avi B. Markowitz
PRINCIPAL_INVESTIGATOR
Site Public Contact
Masey M. Ross
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.